You would like to read
- LTS Investment Fund Ltd picks up stake in Vikas Multicorp Ltd
- Vikas Multicorp Ltd. announces board meeting; to evaluate various opportunities
- Bliss GVS Pharma consolidated net profit declines 33.80% in the September 2020 quarter
- Bliss GVS Pharma consolidated net profit declines 52.09% in the June 2020 quarter
Mumbai (Maharashtra) [India], January 13 (ANI/NewsVoir): As per Bulk deal data available on NSE, Mauritius based LTS Investment Fund has picked up stake in BSE and NSE listed Bliss GVS Pharma Ltd. Earlier, Life Corporation of India (LIC) had also raised stake in Bliss GVS Pharma.
Bliss GVS is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. Today Bliss GVS is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest product portfolio in this segment.
The company's thirty years of experience in suppository manufacturing has resulted in developing an extensive product offering in suppositories and pessaries across various therapeutic categories. Bliss GVS manufacturing plants are certified to be cGMP compliant by local and international standards: EU GMP, WHO GMP, OHSAS-18001 : 2007 and ISO-14001 : 2004. This company is the only EU-GMP certified suppositories manufacturer in India.
It is constantly looking to raise the bar in terms of developing innovative products and quality standards which keeps it ahead of competition in this dosage form. This organisation is proud of its segment leadership in Anti-malarial products across most African markets. Its brands cover an extensive range of Artemisinin-based combination formulations across various dosage forms - Tablets, Suspensions, Sachets, Suppositories and Injections.
The company's sales and Profit before tax have constantly been rising since FY14-15. The company has received many accreditations including "Outstanding Export Performance Award" by Pharmexil, "National Award for Research and Development efforts" and "National Award for Outstanding Efforts in Entrepreneurship".
Bliss GVS Pharma has 8 manufacturing facilities, over 20 therapeutic categories and over 250 products. Over the last decade, Bliss GVS has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities. The company is poised for an accelerated rate of growth.
This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
